The 2012 AHS/AAN Guidelines for Prevention of Episodic Migraine: A Summary and Comparison With Other Recent Clinical Practice Guidelines
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Background.— Updated guidelines for the preventive treatment of episodic migraine have been issued by the American Headache Society (AHS) and the American Academy of Neurology (AAN). We summarize key 2012 guideline recommendations and changes from previous guidelines. We review the characteristics, methods, consistency, and quality of the AHS/AAN guidelines in comparison with recently issued guidelines from other specialty societies. Methods.— To accomplish this, we reviewed the AHS/AAN guidelines and identified comparable recent guidelines through a systematic MEDLINE search. We extracted key data, and summarized and compared the key recommendations and assessed quality using the Appraisal of Guidelines Research and Evaluation‐II (AGREE‐II) tool. We identified 2 additional recent guidelines for migraine prevention from the Canadian Headache Society and the European Federation of Neurological Societies. All of the guidelines used structured methods to locate evidence and linked recommendations with assessment of the evidence, but they varied in the methods used to derive recommendations from that evidence. Results.— Overall, the 3 guidelines were consistent in their recommendations of treatments for first‐line use. All rated topiramate, divalproex/sodium valproate, propranolol, and metoprolol as having the highest level of evidence. In contrast, recommendations diverged substantially for gabapentin and feverfew. The overall quality of the guidelines ranged from 2 to 6 out of 7 on the AGREE‐II tool. Conclusion.— The AHS/AAN and Canadian guidelines are recommended for use on the basis of the AGREE‐II quality assessment. Recommendations for the future development of clinical practice guidelines in migraine are provided. In particular, efforts should be made to ensure that guidelines are regularly updated and that guideline developers strive to locate and incorporate unpublished clinical trial evidence.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Migraine prevalence, disease burden, and the need for preventive therapy
Lipton, R. B., Bigal, M. E., Diamond, M., Freitag, F., Reed, M. L., & Stewart, W. F. (2007) · Neurology · doi:10.1212/01.wnl.0000252808.97649.21 · Cited by 2,337 · cited 1×
“Despite the availability of such up-to-date, evidence-based recommendations, research suggests that a majority of migraine sufferers who would benefit from prevention therapies do not receive them.(5,6) Possible barriers to the adequate preventive treatment of migraine may be lack of physician awareness of the content…”
BackgroundEFNS guideline on the drug treatment of migraine—revised report of an EFNS task force
Evers, S., Áfra, J., Frese, A., Goadsby, P. J., Linde, M., May, A., & Sándor, P. S. (2009) · European Journal of Neurology · doi:10.1111/j.1468-1331.2009.02748.x · Cited by 892
AGREE II: Advancing guideline development, reporting and evaluation in health care
Brouwers, M. C., Kho, M. E., Browman, G. P., Burgers, J. S., Cluzeau, F., Feder, G., Fervers, B., Graham, I. D., Grimshaw, J., Hanna, S. E., et al. (2010) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.07.001 · Cited by 563
Effect of reporting bias on meta-analyses of drug trials: reanalysis of meta-analyses
Hart, B., Lundh, A., & Bero, L. (2012) · BMJ · doi:10.1136/bmj.d7202 · Cited by 255
Wieseler, B., Kerekes, M. F., Vervoelgyi, V., McGauran, N., & Kaiser, T. (2012) · BMJ · doi:10.1136/bmj.d8141 · Cited by 129 · cited 1×
“Some have to do with problems in tagging studies as RCTs in MEDLINE or the need to condense information to meet word limits imposed by medical journals.(28,29) It is clear, however, that much clinical trial evidence has never been published or has been incompletely reported.”
BackgroundOut of sight but not out of mind: how to search for unpublished clinical trial evidence
Chan, A.-W. (2012) · BMJ · doi:10.1136/bmj.d8013 · Cited by 62
Cited by
Opioid Prescribing: A Systematic Review and Critical Appraisal of Guidelines for Chronic Pain
Nuckols, T. K., Anderson, L., Popescu, I., Diamant, A. L., Doyle, B., Di Capua, P., & Chou, R. (2014) · Annals of Internal Medicine · doi:10.7326/0003-4819-160-1-201401070-00732 · Cited by 348
Atogepant for the Preventive Treatment of Migraine
Ailani, J., Lipton, R. B., Goadsby, P. J., Guo, H., Miceli, R., Severt, L., Finnegan, M., & Trugman, J. M. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035908 · Cited by 312
Migraine: integrated approaches to clinical management and emerging treatments
Ashina, M., Buse, D. C., Ashina, H., Pozo-Rosich, P., Peres, M. F. P., Lee, M. J., Terwindt, G. M., Halker Singh, R., Tassorelli, C., Do, T. P., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32342-4 · Cited by 305
Gonçalves, A. L., Martini Ferreira, A., Ribeiro, R. T., Zukerman, E., Cipolla-Neto, J., & Peres, M. F. P. (2016) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2016-313458 · Cited by 169
β-blockers: Their new life from hypertension to cancer and migraine
Fumagalli, C., Maurizi, N., Marchionni, N., & Fornasari, D. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2019.104587 · Cited by 102
Metadata
- Authors
- Loder, E., Burch, R., & Rizzoli, P.
- Venue
- Headache: The Journal of Head and Face Pain
- Publisher
- Wiley
- Published
- 2012-06
- Volume
- 52
- Issue
- 6
- Pages
- 930-945
- ISSN
- 0017-8748 (ISSN-L)
- 1526-4610
- OpenAlex
- W1991627994
- Cited by
- 244
- References
- 6
- FWCI
- 11.48
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.